Omeros Corporation (OMER) is a publicly traded Healthcare sector company. As of May 21, 2026, OMER trades at $12.62 with a market cap of $846.79M and a P/E ratio of 9.45. OMER moved +3.43% today. Year to date, OMER is -19.61%; over the trailing twelve months it is +276.29%. Its 52-week range spans $2.95 to $17.65. Analyst consensus is buy with an average price target of $40.00. Rallies surfaces OMER's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Omeros Reports Q1 Net Income of $56.1M, Launches YARTEMLEA for TA-TMA: Omeros reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, driven by initial commercial sales of YARTEMLEA. The therapy, approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy, began generating revenue as rollout commenced in the quarter.
| Metric | Value |
|---|---|
| Price | $12.62 |
| Market Cap | $846.79M |
| P/E Ratio | 9.45 |
| EPS | $1.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.65 |
| 52-Week Low | $2.95 |
| Volume | 454 |
| Avg Volume | 0 |
| Revenue (TTM) | $9.89M |
| Net Income | $86.17M |
| Gross Margin | 0.00% |
2 analysts cover OMER: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $40.00.